IL1B and neoplasm: Anakinra treatment significantly increased relapse rates from 0% to 50% (Fig 2A) and decreased survival from 100% to 0% (Fig 2B), suggesting that IL-1 plays a role in the anti-tumour efficacy of ingenol mebutate.